Company presentations

Allegria Therapeutics is a Basel-based biopharma start-up established in 2023 with a highly differentiated portfolio of therapeutic approaches to target mast cells as drivers of allergy and inflammatory disease.
Our first-in-class approaches modulate mast cell activity directly and selectively to attain a combination of better efficacy and safety as compared to approaches being pursued thus far.

Atopia Therapeutics, is developing ATP-R13, a first-in-class disease-modifying oral immunotherapy targeting allergic diseases like asthma, atopic dermatitis, and food allergies. Derived from a natural bacterial protein, ATP-R13 restores immune tolerance by inducing regulatory T cells (Tregs), addressing the root cause of allergic inflammation. Atopia aims to provide curative solutions beyond symptom management and is advancing ATP-R13 toward clinical development

May 6, 13:45 - 14:00, room Singapore

Azafaros is a clinical-stage biotech company developing nizubaglustat, an orally available, brain-penetrant small molecule with a unique dual mode of action, targeting key pathways in GM1/GM2 gangliosidoses, Niemann-Pick type C (NPC), and other severe metabolic disorders. Following a successful Ph 2 study, Azafaros is preparing for global Ph 3 trials in GM1/GM2 gangliosidoses and NPC. In parallel, the company continues to expand its pipeline through cutting-edge research.

Basilea is a committed to developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. We have successfully launched two hospital brands, Cresemba® for the treatment of invasive fungal infections and Zevtera® for the treatment of bacterial infections. Basilea is located in the Basel area, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).

Cytiva and Pall Life Sciences have come together to deliver the breadth, depth, and scale researchers and biopharma need to advance future therapeutics – from discovery to delivery. Together, as Cytiva, we supply the tools and support our customers need to work better, faster and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™,

May 5, 16:45 - 17:00, room Osaka/Samarkand

FimmCyte is a Swiss biotech developing disease modifying therapies for chronic diseases through elimination of diseased cells directly. FimmCyte has a pipeline of multi-specifics with the two most advanced assets ready for IND and CMC for endometriosis and an organ fibrosis.

May 6, 13:00 - 13:15, room Singapore

Helbling is an internationally active and independent engineering and consulting firm employing more than 600 professionals with a focus on innovation and product development, management consulting, energy/infrastructure, mergers/acquisitions, restructuring, and real estate. We develop technologically sophisticated products for our clients, from conceptualization to industrialization, and bring innovation to life – a matter of heart, soul and actions.

Labcorp is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. Learn more about us at www.labcorp.com.

May 5, 15:30 - 15:45, room Osaka/Samarkand

Legacy Healthcare is developing treatments for autoimmune diseases. Its first drug, Cinainu, demonstrated efficacy and safety in a Ph 2/3 trial in children and adolescents with Alopecia Areata. Cinainu is a first-in-class botanical drug with patent protection until 2043. Thanks to unparallel safety and efficacy, physicians say Cinainu would be their first-line treatment in a market expected to generate $5b by 2030. The company is raising funds to pursue FDA track.

metaLead is a spin-out from the University of Zurich pioneering innovative therapies for metal-related diseases. Our platform develops first-in-class metal-binding peptides with exceptional affinity and selectivity to desired metals. Our lead program addresses Wilson disease, a rare genetic condition causing the accumulation of toxic amounts of copper in the liver and brain. We combine cutting-edge science, drug development expertise, and patient-driven innovation.

May 6, 13:15 - 13:30, room Singapore

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases.

May 6, 14:15 - 14:30, room Osaka/Samarkand

Neurosterix is a biopharmaceutical company focused on developing allosteric modulators for the treatment of neurological disorders. Our drug discovery and development platform identifies and develops allosteric modulators — molecules that increase or decrease the activity of target receptors by binding outside of the “active site” where endogenous ligands and traditional drugs operate. Through this platform, Neurosterix’s novel drug candidates have the potential to provide me

Parexel is among the world’s largest CROs, providing full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, we collaborate with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials for patients.

May 6, 12:45 - 13:00, room Osaka/Samarkand

ProtaGene is a world-leading CRO partner for the biopharmaceutical and gene and cell therapy industries. From research through product commercialization, we provide the most advanced, integrated, and complete protein and gene analytic capabilities and packages for biologic therapeutics as well as gene and cell therapy platforms including NBE, AAV, mRNA and LV development candidates. Our services comprise extended characterization as well as release and stability testing.

May 6, 15:00 - 15:15, room Osaka/Samarkand

Salvina Therapeutics is developing antibodies with a novel approach for targeting TNF and TNF superfamily members with the aim of improving their safety and efficacy, and facilitating the generation of novel bispecific therapies.

May 5, 15:00 - 15:15, room Singapore

TFS HealthScience is a global contract research organization that partners with biotechnology and pharmaceutical companies throughout their entire clinical development journey. With industry-leading expertise in key therapeutic areas and demand-driven strategic resourcing, TFS can meet the needs of our partners and sponsors. Our experts are passionate about their disciplines, continually learning, enhancing and dedicating themselves to the success of your trial.

Versameb AG is a clinical-stage biotechnology company pioneering RNA-based therapeutics to address unmet medical needs. Its proprietary VERSagile platform optimizes RNA functionality for enhanced therapeutic potential. Lead candidate VMB-100, a novel mRNA therapy for stress urinary incontinence (SUI), is advancing to Phase 2a trials in 2025. Based in Basel, Versameb is committed to transforming medicine through innovative RNA science.